News articles about Inogen (NASDAQ:INGN) have been trending somewhat positive this week, according to Accern. Accern identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Inogen earned a daily sentiment score of 0.12 on Accern’s scale. Accern also assigned news articles about the medical technology company an impact score of 46.0970063307044 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the news articles that may have effected Accern Sentiment’s rankings:
A number of research firms have commented on INGN. Zacks Investment Research lowered Inogen from a “buy” rating to a “hold” rating in a research report on Wednesday. BidaskClub lowered Inogen from a “hold” rating to a “sell” rating in a research report on Saturday, January 6th. Needham & Company LLC increased their target price on Inogen from $108.00 to $125.00 and gave the stock a “strong-buy” rating in a research report on Wednesday, November 8th. Finally, Leerink Swann reissued an “outperform” rating and issued a $120.00 target price (up previously from $115.00) on shares of Inogen in a research report on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. Inogen has a consensus rating of “Hold” and a consensus price target of $102.71.
Shares of Inogen (NASDAQ INGN) traded up $0.42 on Friday, reaching $115.59. The company’s stock had a trading volume of 177,929 shares, compared to its average volume of 135,002. Inogen has a 1-year low of $62.69 and a 1-year high of $130.05. The stock has a market cap of $2,403.64, a P/E ratio of 93.98, a price-to-earnings-growth ratio of 3.90 and a beta of 1.13.
Inogen (NASDAQ:INGN) last issued its earnings results on Tuesday, November 7th. The medical technology company reported $0.33 EPS for the quarter, beating the consensus estimate of $0.29 by $0.04. Inogen had a return on equity of 13.37% and a net margin of 11.36%. The business had revenue of $69.00 million for the quarter, compared to the consensus estimate of $63.55 million. During the same period last year, the business posted $0.25 EPS. The company’s revenue was up 26.8% compared to the same quarter last year. research analysts forecast that Inogen will post 1.19 earnings per share for the current year.
In other news, Director Ray Benjamin M. Anderson sold 1,000 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $119.06, for a total value of $119,060.00. Following the transaction, the director now directly owns 1,000 shares in the company, valued at approximately $119,060. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Raymond Huggenberger sold 14,000 shares of the firm’s stock in a transaction on Monday, October 16th. The stock was sold at an average price of $94.07, for a total value of $1,316,980.00. Following the completion of the transaction, the director now owns 7,808 shares in the company, valued at $734,498.56. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 81,500 shares of company stock worth $9,267,695. Company insiders own 5.31% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/13/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-inogen-ingn-share-price.html.
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.